Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Ablation & Embolization
Chemoembolization of the liver
What chemoembolization of the liver (TACE) is, how interventional radiologists deliver targeted chemotherapy directly to hepatic tumours, what clinical evidence shows for hepatocellular carcinoma and liver metastases, who is eligible, how TACE compares with radiofrequency ablation and surgery, approximate costs across Turkey, the UK, US and Germany, post-embolization recovery milestones, known risks, and essential questions to ask your multidisciplinary medical team.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Ablation & Embolization
- Hospitals
- 2
- Verified
- 1
- Price from
- Price on request
Verified surgeons for Chemoembolization of the Liver
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
Chemoembolization of the liver in Turkey: what it is and how TACE works
Chemoembolization of the liver, or transarterial chemoembolization (TACE), is an image-guided oncology procedure used to treat liver tumours. Performed by an interventional radiologist, it delivers concentrated chemotherapy directly into tumour blood vessels while blocking them with embolic agents. This targeted dual mechanism traps high drug doses inside the tumour to destroy cancer cells and cuts off the oxygen supply needed for tumour growth, while sparing healthy tissues from high systemic exposure.
The liver has a dual blood supply: healthy tissue receives 75 percent of its blood from the portal vein and 25 percent from the hepatic artery. Liver tumours—including hepatocellular carcinoma and hypervascular metastases—derive up to 90 percent of their blood from hepatic artery branches. By targeting these arteries, specialists treat lesions while preserving normal liver tissue. For an overview of care pathways, see our guide to oncology treatments in Turkey.
How does chemoembolization of the liver target tumours?
The procedure combines targeted chemotherapy with microvascular embolization. A thin catheter is inserted through a small puncture in the femoral artery at the groin or the radial artery at the wrist. Under fluoroscopic X-ray guidance, the interventional radiologist advances the catheter through the arterial tree until a microcatheter rests inside the small vessels feeding the tumour.
Once vessel positioning is confirmed with contrast dye, the team delivers the treatment:
- Cytotoxic delivery: In conventional TACE (cTACE), chemotherapy drugs such as doxorubicin or cisplatin are mixed with Lipiodol, an oily medium that pools inside tumour vessels. In drug-eluting bead TACE (DEB-TACE), calibrated microspheres slowly release chemotherapy directly into the tumour over several weeks.
- Ischaemic embolization: Embolic particles are injected to block arterial flow. This stops the chemotherapy from washing away, starves the cancer cells of oxygen, and causes tumour necrosis.
Does chemoembolization of the liver work, and what does the clinical evidence show?
Chemoembolization of the liver is an established treatment supported by clinical trials and recommended by international bodies, including the European Association for the Study of the Liver (EASL) and CIRSE. It is standard care for intermediate-stage (BCLC stage B) hepatocellular carcinoma, where tumours are confined to the liver without main portal vein invasion or distant spread, but surgery is not immediately possible.
Clinical trials show that chemoembolization controls tumour growth, extends survival compared with supportive care, and can shrink tumours to meet criteria for surgical resection or liver transplantation (bridging therapy). It is also used to control symptoms in neuroendocrine tumour metastases and selected colorectal metastases. However, chemoembolization is rarely curative alone; its purpose is disease control and tumour necrosis. In patients with decompensated cirrhosis (Child-Pugh class C) or main portal vein blockage, it does not improve survival and carries high risks of liver failure.
Chemoembolization of the liver cost in Turkey compared with the UK, US and Germany
The cost of liver chemoembolization depends on whether conventional TACE or drug-eluting beads (DEB-TACE) are used, the number of arterial branches treated, the type of sedation, and the length of inpatient stay. The approximate ranges below reflect typical private healthcare fees and are not binding quotes.
| Country | Approximate cost range (per session) |
|---|---|
| Turkey | €3,500 – €7,500 |
| United Kingdom | €8,000 – €16,000 |
| United States | €14,000 – €32,000 |
| Germany | €7,500 – €15,000 |
What influences the price: pre-procedure cross-sectional imaging (triphasic CT or MRI), blood tests, specialist fees, consumable charges (such as microcatheters and drug-eluting beads), and post-procedure medication. In Turkey, packages usually cover the procedure, interventional specialist fees, one to two nights of private hospital monitoring, standard tests, and airport transfers. Always verify in writing whether follow-up imaging or further sessions are included.
Conventional TACE, DEB-TACE or radiofrequency ablation: comparing treatment options
Interventional oncology offers several techniques for treating liver tumours. The choice between conventional chemoembolization (cTACE), drug-eluting bead chemoembolization (DEB-TACE) and local thermal ablation depends on tumour size, location, vascular anatomy and underlying liver health. For small single lesions where thermal destruction is preferred, see our guide to radiofrequency ablation.
| Technique | Best suited to | Typical limits |
|---|---|---|
| Conventional TACE (cTACE) | Multifocal intermediate HCC, bridging to transplant, hypervascular metastases | Requires overnight stay; Lipiodol washes out over time; modest systemic drug exposure |
| DEB-TACE (Drug-Eluting Beads) | Patients needing sustained local drug release with lower systemic circulation | Higher consumable cost; requires catheter engagement in distinct feeding branches |
| Radiofrequency Ablation (RFA) | Solitary or small tumours under 3 cm with clear margins | Less effective for tumours over 3 cm or those near major blood vessels or bile ducts |
While thermal methods like radiofrequency ablation aim to destroy small individual nodules, chemoembolization addresses larger or multifocal tumours across liver segments. Multidisciplinary teams often combine chemoembolization with systemic therapies or ablation. Explore other approaches in our directory of oncology treatments in Turkey.
Who is an appropriate candidate for liver chemoembolization?
Suitability for chemoembolization is assessed by a multidisciplinary tumour board including hepatologists, oncologists, liver surgeons and interventional radiologists. Good candidates typically meet the following criteria:
- Confirmed primary hepatocellular carcinoma (BCLC stage B) or liver-predominant metastases from neuroendocrine tumours or colorectal cancer.
- Preserved liver function, usually Child-Pugh class A or early class B, with near-normal bilirubin and no severe ascites.
- An open, functioning portal vein to maintain ongoing blood supply to normal liver tissue when arterial flow is blocked.
- Good performance status (ECOG score 0 or 1), allowing independent daily activity.
- Acceptable kidney function and safe blood-clotting parameters.
Patients who are not candidates include those with decompensated cirrhosis (Child-Pugh class C, jaundice, encephalopathy), main portal vein thrombosis, extensive tumour replacing over 50 to 70 percent of liver tissue, severe renal failure, or active infection. Embolization in these circumstances risks precipitating liver failure.
What happens during the transarterial chemoembolization procedure step by step?
A chemoembolization session takes place in an interventional radiology suite under sterile conditions and usually lasts 60 to 90 minutes. The procedure involves four steps:
- 1. Vascular access: You lie on the angiography table. Mild intravenous sedation and painkillers keep you relaxed, while local anaesthetic numbs the groin or wrist puncture site. General anaesthesia is rarely required.
- 2. Catheter navigation: The radiologist enters the artery with a fine needle and advances a flexible catheter under X-ray guidance into the hepatic artery. Contrast dye maps the vessels feeding the tumour.
- 3. Microcatheter positioning: A microcatheter under 1 mm in diameter is guided into the specific small branches supplying the tumour, protecting arteries that feed normal liver tissue, the stomach and the gallbladder.
- 4. Drug delivery and embolization: The chemotherapy mixture or drug-eluting beads are infused, followed by embolic particles until tumour blood flow stops. The catheter is removed, and pressure or a closure device seals the puncture.
Recovery after liver chemoembolization and planning your trip to Turkey
After the procedure, you rest flat in bed for four to six hours if femoral access was used. Most patients stay in hospital for one to two nights for hydration, pain relief and monitoring. A total stay in Turkey of six to eight days is usually recommended so your team can track recovery, repeat blood tests, and confirm you are fit to fly.
Recovery milestones include:
- Days 1–3: Up to 80 percent of patients develop post-chemoembolization syndrome, with low fever, right upper abdomen pain, nausea and fatigue. Intravenous fluids and medication control these symptoms, and gentle walking begins the next day.
- Days 4–7: Inpatient discharge occurs once you eat normally and fever resolves. You rest at your hotel, drinking plenty of water. A follow-up consultation and blood check take place before travel.
- Weeks 2–4: Mild tiredness can linger as dead tumour tissue is reabsorbed. Most people return to light desk work after 10 to 14 days, avoiding strenuous exercise until cleared.
- Weeks 4–6: A follow-up CT or MRI scan and tumour marker tests assess response. Further targeted sessions may be scheduled if needed.
Risks, post-embolization syndrome and safety guidelines
Chemoembolization is an established procedure, but like any oncology intervention it carries risks. Professional guidelines divide effects into expected temporary reactions and rarer adverse events.
The most common reaction is post-chemoembolization syndrome (PES). It occurs in up to 80 percent of patients, causing right upper abdomen discomfort, nausea, low fever and fatigue. These symptoms result from inflammatory signals released by dying tumour cells and typically resolve within three to seven days with supportive care.
Other recognised complications include:
- Liver dysfunction: Temporary rises in liver enzymes are common; permanent liver failure is rare and occurs mainly when baseline liver health was already poor.
- Non-target embolization: Inadvertent travel of embolic particles into nearby vessels can cause gallbladder inflammation (cholecystitis), stomach ulcers or pancreatitis. Selective microcatheter technique reduces this risk.
- Biliary injury: Damage to bile ducts (strictures or bilomas) can occur because bile ducts rely entirely on hepatic arterial blood.
- Infection or liver abscess: Dead tumour tissue can become infected, especially in patients with prior biliary surgery, requiring antibiotics or drainage.
- Access-site issues: Bruising or bleeding at the puncture site, and temporary contrast-related kidney strain.
How to choose an interventional radiology hospital in Turkey and red flags
Chemoembolization requires an accredited hospital equipped with advanced digital subtraction angiography suites, intensive care facilities and round-the-clock laboratory support. Your case should be evaluated by a multidisciplinary tumour board rather than a single doctor.
Red flags to watch for:
- Promises of an assured cure or permanent tumour eradication.
- Quotes issued without reviewing recent triphasic CT or MRI scans and blood tests.
- Treatment offered in day-clinics without overnight hospital admission or intensive care backup.
- Unclear specialist qualifications; the operator should be an interventional radiologist experienced in liver procedures.
- No clear emergency plan or arrangements for follow-up communication once you return home.
Questions to ask the clinic:
- Will a multidisciplinary tumour board review my scans and blood tests before I travel?
- Which chemoembolization technique is recommended for my case, and why?
- How does the team manage post-chemoembolization symptoms if recovery takes longer?
- What items, medications and hospital nights are included in the written price?
- How will my follow-up imaging be reviewed after I return home?
Learn more about how our process works or request a hospital review through our free quote page to receive a personalised treatment plan.
Hospitals with Oncology in Turkey
Frequently asked questions
Chemoembolization of the liver, or transarterial chemoembolization (TACE), is an image-guided procedure for treating liver tumours. An interventional radiologist navigates a microcatheter into tumour-feeding hepatic arteries to deliver high doses of chemotherapy directly to cancer cells before blocking blood flow with embolic particles, depriving the tumour of oxygen and nutrients.
Clinical trials show that chemoembolization effectively halts tumour progression, extends survival in intermediate-stage hepatocellular carcinoma, and can shrink tumours to qualify patients for surgical resection or liver transplantation. It is also used to control symptoms in neuroendocrine liver metastases. While effective at causing tumour necrosis, it is rarely curative on its own.
In Turkey, chemoembolization of the liver typically costs between €3,500 and €7,500 per session, compared with €8,000 to €16,000 in the UK and up to €32,000 in the US. The price varies with the technique, microcatheter consumables, and required hospital nights. Each hospital provides an exact price following medical record review.
Follow-up multiphasic contrast CT or MRI scans at four to six weeks typically demonstrate reduced arterial enhancement within treated nodules, indicating successful tumour necrosis. Scans may also show lesion shrinkage or stable disease without new vessel formation. Serum tumour markers such as alpha-fetoprotein are also tracked to confirm therapeutic response.
Most patients stay in hospital for one to two nights for monitoring and symptom management. Initial symptoms such as fatigue, low fever and nausea subside over three to seven days. Most individuals return to light desk work after 10 to 14 days, with full activity resuming after three to four weeks.
The procedure itself is performed under local anaesthesia and mild intravenous sedation, so the catheter insertion is not painful. However, after embolization, most patients experience post-chemoembolization syndrome, causing right upper quadrant abdominal pain and nausea. This discomfort is anticipated and routinely managed with intravenous and oral pain relief.
The duration of disease control varies depending on tumour biology, lesion size, and underlying liver health. Many patients achieve local disease stabilisation for several months to over a year. Because liver tumours can form new feeding vessels or recur, repeat chemoembolization sessions or complementary therapies are frequently used to maintain control.
Chemoembolization is an established interventional radiology procedure with a recognised safety profile. Mild post-chemoembolization syndrome occurs in most patients and resolves within a week. Serious complications such as liver failure, infection or unintended embolization are uncommon when patients are screened for adequate liver reserve by an experienced multidisciplinary team.
Radiofrequency ablation uses heat to destroy small tumours under 3 cm completely and is often aimed at curative local control. Chemoembolization treats larger or multiple tumours across liver lobes by blocking their arterial blood supply. The two modalities are complementary and are sometimes combined in comprehensive cancer treatment plans.
Patients are advised to plan a stay of six to eight days in Turkey. This duration covers pre-procedural imaging and blood tests, the catheterisation procedure, one to two nights of inpatient hospital monitoring, and a follow-up consultation with repeat blood checks to confirm safe recovery before flying home.
Patient stories